CD274 and Leigh syndrome: Although ICIs are not approved for LS-SCLC, triplet therapy with anti-PD-L1 therapies (e.g., atezolizumab or durvalumab) combined with platinum/etoposide are the SoC therapy for ES-SCLC [11, 12].